CLEVELAND, OH – March 29, 2016
Sujana Biotech announces funding from the National Heart Lung and Blood Institute to support the development of a novel anti-thrombotic therapeutic. BioAtla, a long time collaborator, was awarded a Phase I SBIR grant of $220,268 to support the development of Sujana’s platform technology. The technology has potential applications over a range of inflammatory and vascular disorders.
Sujana, launched by BioMotiv, is based on technology licensed from Case Western Reserve University and University Hospitals in Cleveland, with collaborators at the Cleveland Clinic.